* participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) * participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature \>= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit \[°f\]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator * participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) * participant has history of capillary leak syndrome * participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination) * participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

* participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) * participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature \>= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit \[°f\]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator * participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) * participant has history of capillary leak syndrome * participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination) * participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit [°f]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) participant has history of capillary leak syndrome participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination) participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit [°f]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) participant has history of capillary leak syndrome participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination) participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

None

None

participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit [°f]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) participant has history of capillary leak syndrome participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination) participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

participant has a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit [°f]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) participant has history of capillary leak syndrome participant received a licensed/registered severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination (other than study vaccination) participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

- participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) - participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit [°f]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator - participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) - participant has history of capillary leak syndrome - participant received or plans to receive a severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination or during the course of this study (other than study vaccination) - participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood

- participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancies considered cured with minimal risk of recurrence per investigator's clinical judgment) - participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature >= 38.0 degrees celsius (ºc) (100.4 degrees fahrenheit [°f]) within 24 hours prior to the planned dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator - participant has history of thrombosis with thrombocytopenia syndrome (tts) or heparin-induced thrombocytopenia and thrombosis (hitt) - participant has history of capillary leak syndrome - participant received or plans to receive a severe acute respiratory syndrome coronavirus(-2) (sars-cov-2) vaccine less than 6 months prior to first study vaccination or during the course of this study (other than study vaccination) - participant has a history of any neurological disorders or seizures including guillain-barre syndrome, with the exception of febrile seizures during childhood